Most common treatment regimens by LOT
| Most common treatment regimens . | n (%) . |
|---|---|
| 2L (N = 1283) | |
| Ibrutinib | 431 (33.6) |
| Bendamustine, rituximab | 204 (15.9) |
| Acalabrutinib | 118 (9.2) |
| Investigational regimen | 76 (5.9) |
| Rituximab | 70 (5.5) |
| Rituximab, venetoclax | 56 (4.4) |
| Chlorambucil, obinutuzumab | 32 (2.5) |
| Venetoclax | 31 (2.4) |
| Obinutuzumab, venetoclax | 29 (2.3) |
| Cyclophosphamide, fludarabine, rituximab | 26 (2.0) |
| Other treatment regimens | 210 (16.4) |
| 3L (N = 542) | |
| Ibrutinib | 133 (24.5) |
| Acalabrutinib | 75 (13.8) |
| Bendamustine, rituximab | 47 (8.7) |
| Venetoclax | 35 (6.5) |
| Rituximab, venetoclax | 34 (6.3) |
| Rituximab | 24 (4.4) |
| Investigational regimen | 22 (4.1) |
| Obinutuzumab, venetoclax | 17 (3.1) |
| Idelalisib, rituximab | 15 (2.8) |
| Chlorambucil | 11 (2.0) |
| Other treatment regimens | 129 (23.8) |
| 4L (N = 228) | |
| Ibrutinib | 42 (18.4) |
| Acalabrutinib | 26 (11.4) |
| Rituximab, venetoclax | 22 (9.6) |
| Venetoclax | 18 (7.9) |
| Bendamustine, rituximab | 16 (7.0) |
| Investigational regimen | 16 (7.0) |
| Rituximab | 11 (4.8) |
| Idelalisib, rituximab | 9 (3.9) |
| Obinutuzumab | 8 (3.5) |
| Ibrutinib, rituximab | 7 (3.1) |
| Other treatment regimens | 53 (23.2) |
| Most common treatment regimens . | n (%) . |
|---|---|
| 2L (N = 1283) | |
| Ibrutinib | 431 (33.6) |
| Bendamustine, rituximab | 204 (15.9) |
| Acalabrutinib | 118 (9.2) |
| Investigational regimen | 76 (5.9) |
| Rituximab | 70 (5.5) |
| Rituximab, venetoclax | 56 (4.4) |
| Chlorambucil, obinutuzumab | 32 (2.5) |
| Venetoclax | 31 (2.4) |
| Obinutuzumab, venetoclax | 29 (2.3) |
| Cyclophosphamide, fludarabine, rituximab | 26 (2.0) |
| Other treatment regimens | 210 (16.4) |
| 3L (N = 542) | |
| Ibrutinib | 133 (24.5) |
| Acalabrutinib | 75 (13.8) |
| Bendamustine, rituximab | 47 (8.7) |
| Venetoclax | 35 (6.5) |
| Rituximab, venetoclax | 34 (6.3) |
| Rituximab | 24 (4.4) |
| Investigational regimen | 22 (4.1) |
| Obinutuzumab, venetoclax | 17 (3.1) |
| Idelalisib, rituximab | 15 (2.8) |
| Chlorambucil | 11 (2.0) |
| Other treatment regimens | 129 (23.8) |
| 4L (N = 228) | |
| Ibrutinib | 42 (18.4) |
| Acalabrutinib | 26 (11.4) |
| Rituximab, venetoclax | 22 (9.6) |
| Venetoclax | 18 (7.9) |
| Bendamustine, rituximab | 16 (7.0) |
| Investigational regimen | 16 (7.0) |
| Rituximab | 11 (4.8) |
| Idelalisib, rituximab | 9 (3.9) |
| Obinutuzumab | 8 (3.5) |
| Ibrutinib, rituximab | 7 (3.1) |
| Other treatment regimens | 53 (23.2) |